Full Press Release Details
Announces Name Change to PharmaCyte Biotech
Company's Shares Will
Trade under New Ticker Symbol PHCB
SPRING, MD, January 7, 2014 (GLOBE NEWSWIRE) - Nuvilex, Inc. (OTCQB: NVLX) today announced that the Company has changed its
name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol "PHCB" on the
OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014.
The name change is part of the Company's transformation process
to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box technology, a proprietary cell encapsulation
platform being utilized to develop "targeted" treatments for solid cancerous tumors and insulin dependent diabetes.
"Over the past year, we've
implemented an aggressive strategy to facilitate the advancement of the treatments we are developing for cancer and diabetes, with
our Cell-in-a-Box technology at the core of these treatments. Our new name reflects the tremendous progress we've
accomplished in terms of clinical development and signifies the structural completion of our transition to becoming a fully dedicated
biotechnology company," said Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
Some of the highlights in 2014 that have
marked this transition include:
"With exciting developments on the
horizon for 2015, our work to develop treatments for both cancer and diabetes will move forward under our new name because it speaks
to what we actually do here at PharmaCyte Biotech," concluded Mr. Waggoner.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary
cellulose-based live cell encapsulation technology known as Cell-in-a-Box . This unique and patented technology
will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer,
and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer
prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing"
form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the
cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past
clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic
cancer and on treatments for other types of solid cancerous tumors. PharmaCyte Biotech is also developing treatments for cancer
based upon chemical constituents of marijuana known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit
the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing
or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech
the rare opportunity to develop "green" approaches to fighting deadly diseases, such as cancer of the pancreas, brain
and breast, which affect hundreds of thousands of individuals worldwide every year.
This press release may contain forward-looking
statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words
"anticipate," "believe," "estimate," "expect," "intend," "plan" and
similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially
from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays
or unsuccessful results in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation
or regulatory requirements, uncertainty of protection of PharmaCyte Biotech's intellectual property and PharmaCyte Biotech's
continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.
information about PharmaCyte Biotech can be found at www.PharmaCyteBiotech.com.
It can also be obtained by contacting Investor Relations.
Investor Relations Contacts:
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103